MARK2 and melanoma: Hou et al. also reported that the B-Raf serine/threonine kinase was the most frequently mutated proto-oncogene in gynecological MM, occurring at a rate of 26% compared to 8.3% in patients with mucosal non-gynecological melanoma, whereas phosphatidylinositol 3-kinase pathway mutations and estrogen receptor/progesterone receptor overexpression were rare [26].